Crotoxin
≈ 4 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Crotoxin (CTX) is the main toxic compound in the snake venom of the South American rattlesnake, Crotalus durissus terrificus. Crotoxin is a heterodimeric beta-neurotoxin, composed of an acidic, non-toxic and non-enzymatic subunit (CA), and a basic, weakly toxic, phospholipase A2 protein (CB). This neurotoxin causes paralysis by both pre- and postsynaptic blocking of acetylcholine signalling.
Crotoxin (CTX) is the main toxic compound in the snake venom of the South American rattlesnake, Crotalus durissus terrificus. Crotoxin is a heterodimeric beta-neurotoxin, composed of an acidic, non-toxic and non-enzymatic subunit (CA), and a basic, weakly toxic, phospholipase A2 protein (CB). This neurotoxin causes paralysis by both pre- and postsynaptic blocking of acetylcholine signalling.
History
Crotoxin was identified in 1938 by researchers of the Department of Chemistry of the Instituto Butantan in São Paulo. The compound was first purified from the venom of Crotalus d. terrificus. These researchers found that 60 per cent of the venom consisted of a neurotoxic substance, later referred to as crotoxin. Crotoxin was the first proteinic toxin to be crystallized (Protein crystallization). The first publication of this discovery showed that the toxin worked with two elements, a toxic and a coagulating principle. Later it was discovered that the crotoxin protein is not homogeneous, but consists of two subunits. The toxic effect of crotoxin is determined mainly by the phospholipase A2 action of CB. The CA subunit is non-enzymatic and non-toxic, but has blood coagulating functions (Coagulation), now known as crotapotin. Since 1966 until today, investigations into pharmacological applications for crotoxin are conducted.
Structure and reactivity
The structure of crotoxin is composed by the components CA and CB in a 1:1 molecular ratio.܁CA is a nontoxic and non-enzymatic acidic protein while CB is the toxic component, a phospholipase A2 protein. Both components form a noncovalent heterodimeric complex (Protein dimer). It was found that isoforms (Protein isoform) of CA and CB can form at least 16 distinct CTX complexes.
Mechanism of action
The primary mechanistic action of crotoxin is twofold, a presynaptic and a postsynaptic action.
Toxicity
Crotoxin has fatal neurotoxic effects, as the toxicity of CB is synergistically intensified by CA. Many people die of acute renal failure or acute respiratory failure. The latter is a result of muscle paralysis in the respiratory system. Low crotoxin levels produce an incomplete blockage of the acetylcholine receptor resulting in paresis, which is fully reversible. At higher doses, neuromuscular impairment is more severe. Also other cholinergic symptoms are common, especially at higher doses. Intramuscular injection of crotoxin further shows myotoxic effects. The intravenous LD50 (Median lethal dose) of native crotoxin is 0.096 μg/g in mice. It has been reported that mice can develop a tolerance to the toxin when they get increasing doses of crotoxin every day. They can eventually tolerate doses up to 35 times the LD50 without being intoxicated. Preclinical studies on human patients also show that toxicity signs decreased or disappeared when the patients were exposed to crotoxin over longer periods of time.
Treatment
In Brazil, each year almost 2,000 snakebites are due to Crotalus durissus. The only treatment for people who are envenomed by C. durissus is a specifically developed antivenom that has to be injected intravenously. With the arrival of this antivenom, the fatality rate declined from 73% to 1.5%. The dosage of the antivenom varies between 10 and 20 ampules depending on the severity of the envenoming. However, the efficacy of the doses have not been clinically examined.
Efficacy
Crotoxin in C. durissus venom is a potent neurotoxin, which also causes renal- and myotoxic effects. Except for its toxic effects, crotoxin also shows anti-inflammatory, immunomodulatory, anti-HIV and anti-tumor effects in human and animal models. Together with the fact that the body can build up tolerance to the toxic effects of crotoxin, these effects are of interest for pharmaceutical use.
Pharmaceutical applications
As Crotoxin works as a neuromuscular blocker (Neuromuscular-blocking drug), some studies have already been conducted to investigate whether Crotoxin could function as a therapy for muscle tension problems. In one study, Crotoxin has shown to improve the ocular alignment of a group of cross-eyed patients after injection. The same study has also shown that it might help patients with blepharospasm. At low concentrations of crotoxin, patients with muscle dystonias show normal function. Therefore, it is proposed as a good alternative for botulinum toxin. Clinical research has shown that the crotoxin complex and isolated CB have antigenic characteristics, which can stimulate antibody production. Some studies have shown crotoxin to improve symptoms related to immune-associated disease and other conditions, including cancer. However, there are currently no NCI (National Cancer Institute) supported clinical trials studying crotoxin for cancer treatment.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371946483 under CC BY-SA 4.0; modifications have been made.